Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.54 |
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596443 | 0.93 | FLT3 (0.64) | FLT3KDRFGFR3 | |
| SCHEMBL3324118 | 0.83 | FLT3 (0.56) | FLT3KDRFGFR3 | |
| SCHEMBL3318754 | 0.79 | FLT3 (0.62) | FLT3KDRFGFR3 | |
| SCHEMBL3323622 | 0.79 | KDR (0.55) | FLT3KDRFGFR3 | |
| SCHEMBL3325023 | 0.76 | FLT3 (0.57) | FLT3KDRFGFR3GABRG2GABRB3 | |
| Formic Acid SCHEMBL3585405 | 0.76 | KDR (0.65) | FLT3KDRFGFR3 | |
| SCHEMBL3590857 | 0.74 | KDR (0.66) | FLT3KDRFGFR3 | |
| Formic Acid SCHEMBL3321629 | 0.73 | FLT3 (0.85) | FLT3KDRFGFR3 | |
| SCHEMBL3328696 | 0.73 | KDR (0.80) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3327918 | 0.73 | KDR (0.66) | FLT3KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | claimed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | FLT3 16/4885KDR 7/4885FGFR3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.